Recursion Pharmaceuticals, Inc. Class A Common Stock
Compare this stock
RXRX Stock Report Card
$
23%
Performance
Score:
10/100
RXRX returned -39.36% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Technicals
Score:
61/100
RXRX receives a 60 of 100 based on 14 indicators. 8 are bullish, 5 are bearish.
Earnings
Score:
10/100
RXRX has missed earnings 6 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 15 quarters, RXRX has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
40/100
RXRX has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.
Recursion Pharmaceuticals, Inc. Class A Common Stock Summary
Nasdaq / RXRX
Healthcare
Biotechnology
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
RXRX scored poorly on our reportcard. Here are some similar companies and how they performed.
